HWK-007

· Whitehawk Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HWK-007, covering 2026-03-27 to 2026-03-27. Get the full timeline:

Most recent: Clinical Trial Update: Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors [Phase 1]

See pricing